» Elixir Announces Completion Of Enrollment In Pivotal Phase III Clinical Trial For New Diabetes Drug
Elixir Pharmaceuticals, Inc., announced that it has completed enrollment in its final pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes. The study is…